Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41031 | 0.98 | TSHR (0.36) | TSHRTHRBGABRR1 | |
| Hydrochloric Acid SCHEMBL2533776 | 0.96 | TSHR (0.35) | TSHRTHRBGABRR1 | |
| Chloromethane SCHEMBL543091 | 0.94 | TSHR (0.34) | TSHRTHRB | |
| Acetic Acid SCHEMBL8433810 | 0.92 | TSHR (0.37) | TSHRTHRBGABRR1 | |
| Sulfuric Acid SCHEMBL5068577 | 0.91 | TSHR (0.32) | TSHRTHRB | |
| Acrylic Acid SCHEMBL8037578 | 0.88 | TSHR (0.34) | TSHR | |
| Acrylamide SCHEMBL9647386 | 0.88 | TSHR (0.37) | TSHR | |
| SCHEMBL446080 | 0.86 | TSHR (0.39) | TSHRTHRB | |
| SCHEMBL10794570 | 0.86 | TSHR (0.30) | TSHR | |
| SCHEMBL13372705 | 0.86 | TSHR (0.33) | TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227496-B1 | CATIONIC BEATAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES | UNIV WASHINGTON (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8404224-B2 | Cationic betaine precursors to zwitterionic betaines having controlled biological properties | UNIVERSITY OF WASHINGTON (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130011363-A1 | CATIONIC BETAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES | UNIVERSITY OF WASHINGTON (US) | 2013-01-10 | — | — | US | disclosed |
| US-8268301-B2 | For drug delivery or biodrug delivery; acrylic type monomers; hydrolyzable group is hydrolyzable to an anionic center to provide a zwitterionic polymer having the anionic center covalently coupled to the cationic center through the second linker | UNIVERSITY OF WASHINGTON (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2227496-A1 | CATIONIC BEATAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES | University of Washington (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090156460-A1 | CATIONIC BETAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES | UNIVERSITY OF WASHINGTON (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2009067562-A1 | CATIONIC BEATAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES | UNIVERSITY OF WASHINGTON (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156460-A1 | CATIONIC BETAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES | SLC6A12, BHMT, PHOSPHO1 | TSHR 3743/4885THRB 947/4885GABRR1 1682/4885 |
| US-20130011363-A1 | CATIONIC BETAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES | SLC6A12, BHMT, PHOSPHO1 | TSHR 3743/4885THRB 947/4885GABRR1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.